HGP1910

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyPrimary Hypercholesterolemia

Phase 1

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903

CompletedNCT04762407

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2020-11-20End: 2021-02-24Updated: 2022-07-14

Phase 3

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

CompletedNCT04652349

Hanmi Pharmaceutical Company LimitedPrimary Hypercholesterolemia

Start: 2020-07-06End: 2021-01-14Updated: 2021-03-05

Related Papers

Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study

Clinical Therapeutics2021-08-2118 citations